Periodic Reporting for period 1 - StaphIMPACT (SA.100: Next-generation targeted antibacterial product entering European market)
Reporting period: 2019-07-01 to 2020-06-30
The randomized controlled clinical study of Gladskin in eczema patients had a good start, but had to be halted due to coronavirus measures. The study has recently restarted and is expected to be completed this year. A significant increase in the number of employees has taken place already.
Gladskin has been made available throughout Europe. It has shown benefit in patients suffering from eczema, rosacea, acne and shaving irritation. Several advantages over the current state of the art OTC treatments for these indications make it highly attractive. During this project the efficacy of Gladskin in eczema will be further established in the ongoing study, expecting to disrupt the OTC eczema treatment market. This is expected to result in a further growth of employment and company profitability.